Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centhaquine for vasopressor-dependent vasodilatory hypotension
ACTRN12624000384550Phase 2Recruiting
- Sponsor
- Austin Health
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypotension and Vasodilatory shock comparing Centhaquine with Placebo (2 arms). Primary endpoint: Stroke volume. Started Oct 2024; status: recruiting.
02
Drugs
centhaquine
03
Conditions
hypotensionVasodilatory shock
Beyond the preview
Go deeper on ACTRN12624000384550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624000384550.